Every cell that responds to vitamin D must also be able to shut the signal off. CYP24A1¹¹ CYP24A1
Cytochrome P450 Family 24 Subfamily A Member 1, also called 25-hydroxyvitamin D-24-hydroxylase — a mitochondrial enzyme that adds a hydroxyl group at the C-24 position of vitamin D metabolites, initiating their breakdown into inactive calcitroic acid encodes the enzyme that serves as the primary off-switch for vitamin D signaling. It degrades both the circulating storage form (25(OH)D²² 25(OH)D
25-hydroxyvitamin D, the form measured in standard blood tests and the primary indicator of vitamin D status) and the potent active hormone (1,25(OH)₂D³³ 1,25(OH)₂D
1,25-dihydroxyvitamin D (calcitriol), the hormonally active form of vitamin D that binds to VDR and regulates hundreds of genes). The variant rs6013897, located near the CYP24A1 gene on chromosome 20, influences how much of this catabolic enzyme your cells produce — and therefore how quickly your body breaks down its vitamin D supply.

The Mechanism

CYP24A1 sits in the mitochondrial inner membrane and catalyzes a multi-step oxidation that converts active vitamin D metabolites into calcitroic acid⁴⁴ calcitroic acid
The water-soluble end-product of vitamin D catabolism, excreted in bile; biologically inactive, which is excreted in bile. The enzyme acts on both 25(OH)D₃ and 1,25(OH)₂D₃, making it the central gatekeeper of vitamin D availability. Importantly, CYP24A1 expression is itself induced by active vitamin D through VDR — forming a negative feedback loop⁵⁵ negative feedback loop
When 1,25(OH)₂D activates VDR, one of the genes VDR upregulates is CYP24A1, which then degrades the 1,25(OH)₂D that activated it — an elegant self-limiting circuit that prevents vitamin D toxicity.

The rs6013897 variant sits in a regulatory region near CYP24A1 and influences the gene's expression level. The A allele is associated with altered enzyme activity that leads to faster degradation of circulating vitamin D metabolites, resulting in lower serum 25(OH)D concentrations. Each copy of the A allele reduces circulating 25(OH)D by approximately 0.74 nmol/L⁶⁶ 0.74 nmol/L
Jorde R et al. Bone mineral density is associated with vitamin D related rs6013897. PLOS ONE, 2017. While this per-allele effect appears modest in isolation, it compounds meaningfully with variants in other vitamin D pathway genes.

The Evidence

The landmark GWAS by Wang et al.⁷⁷ GWAS by Wang et al.
Wang TJ et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010 identified rs6013897 as the fourth genome-wide significant locus for serum 25(OH)D levels (P = 6.0×10⁻¹⁰ in 33,996 Europeans), alongside GC (vitamin D binding protein), DHCR7/NADSYN1 (synthesis), and CYP2R1 (25-hydroxylation). Critically, individuals in the highest quartile of a combined genetic risk score across these loci had 2.47-fold increased odds of vitamin D insufficiency (<75 nmol/L) compared to the lowest quartile.

This finding was reinforced by a larger GWAS in 79,366 individuals⁸⁸ larger GWAS in 79,366 individuals
Jiang X et al. Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nat Commun, 2018 that confirmed CYP24A1 as one of six loci collectively explaining 38% of the total genetic variance in circulating 25(OH)D.

A randomized controlled trial⁹⁹ randomized controlled trial
Barry EL et al. Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation. J Clin Endocrinol Metab, 2014 demonstrated that rs6013897 modifies the response to 1,000 IU/day vitamin D3 supplementation, with each copy of the risk allele reducing the 25(OH)D increase by approximately 4.2% (P = 0.04). This means carriers of the A allele get less benefit from standard supplementation doses because they degrade vitamin D faster.

The Tromsø Study¹⁰¹⁰ Tromsø Study
Jorde R et al. Bone mineral density is associated with vitamin D related rs6013897. PLOS ONE, 2017 extended these findings to bone health, showing that each A allele was associated with lower total hip bone mineral density (β = −0.031, P = 0.024) in 4,039 participants, with AA homozygotes averaging 0.02 g/cm² lower hip BMD than TT homozygotes.

Practical Implications

If you carry one or two A alleles, your body degrades vitamin D faster than average. Standard supplementation doses may not raise your 25(OH)D levels as effectively as they would for someone with the TT genotype. The key implication is that you may need higher doses of vitamin D3 to achieve and maintain optimal blood levels, and you should verify with blood testing rather than assuming a standard dose is sufficient.

This becomes especially important in combination with other vitamin D pathway variants. If you also carry risk alleles in GC (reduced transport), CYP2R1 (reduced activation), VDR (reduced receptor activity), or DHCR7 (reduced synthesis), the cumulative effect on vitamin D status can be substantial.

Interactions

CYP24A1 rs6013897 occupies a unique position in the vitamin D pathway — it is the only catabolic gene among the four GWAS-identified vitamin D loci. While GC (rs4588, rs7041) affects transport, CYP2R1 (rs10741657) affects activation, and DHCR7/NADSYN1 (rs7940244) affects synthesis, CYP24A1 controls degradation. Carrying risk alleles at multiple points in this pathway creates compounding insufficiency: less vitamin D synthesized, less efficiently activated, less effectively transported, AND faster degraded. The Wang et al. combined genetic risk score quantified this at 2.47-fold increased odds of insufficiency for the worst-case combination. VDR FokI (rs2228570) adds another layer — if the receptor itself is less active, even the vitamin D that survives CYP24A1 degradation has reduced biological effect.

Methionine synthase (MTR), also known as MS, carries out one of the most important reactions in human metabolism: it converts homocysteine¹¹ homocysteine
Homocysteine: a potentially toxic amino acid that builds up when the methylation cycle is impaired back into methionine using methylcobalamin (active B12) as a cofactor and 5-methylTHF (methylfolate) as the methyl donor. This single reaction links folate metabolism and B12 status, and when it falters, homocysteine rises and methylation capacity falls.

rs10925260 is an intronic variant in the MTR gene — it does not change the protein sequence directly. Intronic variants can still influence gene function by altering splicing efficiency, mRNA stability, or regulatory element binding, but the exact mechanism for this particular variant has not been characterized at the molecular level.

The Mechanism

Because rs10925260 lies within an intron (c.2677-335A>C in one transcript, ²² c.2677-335A>C notation: 335 base pairs upstream of exon boundary, on the forward strand placing it 335 base pairs upstream of an exon boundary), its most likely functional role is as a tag SNP³³ tag SNP
Tag SNP: a variant in linkage disequilibrium with a nearby functional variant, acting as a proxy marker for that variant's effect in linkage disequilibrium with a nearby functional variant, or a subtle regulatory element affecting MTR expression levels. Ensembl VEP scores this variant with a CADD score⁴⁴ CADD score
CADD: Combined Annotation Dependent Depletion score — higher scores indicate greater predicted deleteriousness; 0.38 is very low of 0.38 and GERP conservation of −1.84, both suggesting minimal evolutionary constraint. This is consistent with a common regulatory tag SNP rather than a strongly functional coding change.

The Evidence

The most direct evidence for rs10925260 comes from a replication study⁵⁵ replication study
Pangilinan F et al. Replication and exploratory analysis of 24 candidate risk polymorphisms for neural tube defects. BMC Med Genet, 2014 by Pangilinan and colleagues, who tested 24 candidate SNPs in folate-pathway genes across independent cohorts (530 UK NTD trios and 190 New York State cases with 941 controls). Of the 24 SNPs tested, MTR rs10925260 was one of only two that reached nominal statistical significance for isolated neural tube defects (along with ADA rs452159). The authors note this association did not survive correction for multiple comparisons across all 24 tests, and they call for additional independent replication.

Neural tube defect risk is one of the most folate-sensitive outcomes in human biology — the MTR pathway is directly implicated because adequate methylation requires both B12-dependent MTR activity and upstream methylfolate supply from MTHFR. Studies of the well-characterized MTR coding variant A2756G⁶⁶ A2756G
Li et al. MTR A2756G associated with increased NTD risk in Chinese population. 2015 (rs1805087) show a modest association with NTD risk (OR 1.45, 95% CI 1.06–1.98), providing biological plausibility for the rs10925260 finding via a shared pathway.

The broader MTR gene context also links B12 metabolism to cardiovascular risk⁷⁷ cardiovascular risk
Klerk M et al. MTR 2756A>G and CHD risk, 2003, homocysteine elevation, and one-carbon metabolism efficiency — all traits where subtle differences in MTR expression could matter.

Practical Implications

Given the emerging and unconfirmed evidence, this variant should not drive supplementation decisions on its own. However, carriers of one or two A alleles (AA or AC genotype) can reasonably prioritize active B12 forms and methylfolate as a precautionary measure, especially women of childbearing age given the NTD association. The form of B12 matters: methylcobalamin and hydroxocobalamin bypass the conversion steps that require MTR to be fully functional, whereas cyanocobalamin still requires enzymatic processing.

Interactions

rs10925260 sits in the same gene as the better-characterized MTR A2756G variant (rs1805087). If you carry variants at both loci, the combined effect on MTR expression and function is unknown but potentially additive. The MTR enzyme works in tandem with MTRR (rs1801394), which reactivates oxidized B12 after each MTR reaction cycle, and upstream MTHFR (rs1801133 C677T, rs1801131 A1298C), which supplies the methylfolate substrate. Weakness at multiple points in this system compounds the impact on homocysteine clearance and methylation capacity.

The SLC30A8 gene¹¹ SLC30A8 gene
SLC30A8 encodes the ZnT8 zinc transporter, expressed almost exclusively in pancreatic beta cells, where it pumps zinc into insulin secretory granules sits at one of the most replicated type 2 diabetes risk loci in the human genome. Most attention has focused on the missense variant rs13266634 (Arg325Trp)²² rs13266634 (Arg325Trp)
rs13266634 changes amino acid 325 from arginine to tryptophan and is the lead coding variant at this locus, but the locus harbors additional variants with independent functional significance. rs11558471 is a 3′ untranslated region (3′-UTR) variant that provides a distinct layer of information about how this locus influences ZnT8 biology and metabolic risk.

The Mechanism

rs11558471 sits in the 3′-UTR of SLC30A8 — the portion of the mRNA that is transcribed but not translated into protein. This region controls mRNA stability, translation efficiency, and the binding of regulatory microRNAs. Unlike rs13266634, which changes the ZnT8 protein sequence, rs11558471 influences how much ZnT8 protein the beta cell produces.

A 2023 study mapping the chromatin architecture of the SLC30A8 locus³³ 2023 study mapping the chromatin architecture of the SLC30A8 locus
Hu et al. Multiple genetic variants at the SLC30A8 locus affect local super-enhancer activity and influence pancreatic β-cell survival and function. FASEB Journal, 2023 identified an islet-selective super-enhancer cluster spanning ~293 kb near the SLC30A8 promoter. Within this landscape, rs11558471 showed the most significantly imbalanced allele-specific expression of any variant tested (⁴⁴ p=4.64×10⁻¹⁴): the risk A allele is preferentially transcribed over the protective G allele. This means A/A carriers produce more ZnT8 protein — and importantly, CRISPR deletion of the enhancer regions in human beta cells reduced SLC30A8 expression and improved glucose-stimulated insulin secretion, consistent with the counterintuitive finding that lower ZnT8 activity is metabolically beneficial.

rs11558471 is in very tight linkage disequilibrium⁵⁵ linkage disequilibrium
Linkage disequilibrium (LD) means two variants are inherited together so frequently they carry correlated information; r²=0.96 means 96% of the statistical variance of one variant is explained by the other with rs13266634 (r²=0.96), so most people who carry the rs11558471 A allele also carry the rs13266634 C (risk) allele. They tag the same biological signal through complementary mechanisms: one affecting protein structure, the other affecting expression level.

The Evidence

A 14-cohort meta-analysis⁶⁶ 14-cohort meta-analysis
Zheng J-S et al. Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis. Diabetes, 2011 of up to 45,821 participants established rs11558471 A as the glucose-raising allele and showed a significant gene-nutrient interaction: each additional milligram per day of total zinc intake attenuated the glucose-raising effect of the A allele (β = −0.0017 per A allele per mg/day zinc, interaction p=0.005). The effect was dose-responsive — A/A homozygotes benefited roughly twice as much from increasing zinc intake as A/G heterozygotes, and the interaction was significant only for total zinc (including supplements), not dietary zinc alone.

In a Malay population study⁷⁷ Malay population study
Teh AL et al. Increased DNA methylation of the SLC30A8 gene promoter is associated with type 2 diabetes in a Malay population. Clinical Epigenetics, 2015 of 992 subjects, the A allele was significantly associated with type 2 diabetes (OR=1.334, 95% CI 1.110–1.602, p=0.002). The same study found that T2D patients also showed higher methylation of the SLC30A8 promoter compared to normoglycaemic controls (82.9% vs 80.1%, p=0.014), suggesting that both genetic variation and epigenetic silencing converge to reduce ZnT8 function in diabetes.

A Chinese Han population study⁸⁸ Chinese Han population study
Xu J et al. SLC30A8 (ZnT8) variations and type 2 diabetes in the Chinese Han population. Genetics and Molecular Research, 2012 confirmed the risk association: the AA genotype was found in 46% of T2D cases versus 24% of controls, and A-containing haplotypes predicted diabetes risk independently of rs13266634.

In South Asian Punjabi populations⁹⁹ South Asian Punjabi populations
Chambers JC et al. Effects of 16 genetic variants on fasting glucose and type 2 diabetes in South Asians: ADCY5 and GLIS3 variants may predispose to type 2 diabetes. PLOS One, 2011, the A allele was nominally associated with higher fasting glucose (β=0.063, p=0.015) in normoglycaemic controls.

A small study of postmenopausal women¹⁰¹⁰ postmenopausal women
Costa SK et al. Relationship between the single nucleotide polymorphism rs11558471 in the SLC30A8/ZnT8 gene and cardiometabolic markers in postmenopausal women. Biological Trace Element Research, 2023 found that G allele carriers had significantly lower LDL-cholesterol than A/A homozygotes (p=0.035), adding a lipid dimension to the variant's metabolic footprint.

Practical Implications

The actionable insight from this variant is the same as from rs13266634 — zinc nutrition modifies risk — but with a mechanistic twist: here the issue is ZnT8 overexpression, not just altered protein function. The 14-cohort data show that zinc supplementation (not just dietary zinc alone) is the relevant lever for A allele carriers, and that A/A homozygotes gain the most from optimizing their zinc status.

For G allele carriers, this locus is a partial explanation for naturally efficient beta-cell zinc handling and lower T2D risk — their beta cells produce less ZnT8, which paradoxically supports better insulin secretion.

Interactions

rs11558471 and rs13266634 are in tight LD (r²=0.96) and largely tag the same signal. Carriers of the A allele here almost invariably carry the C allele at rs13266634. The combined picture is higher ZnT8 expression (rs11558471 mechanism) driving a protein with altered zinc transport kinetics (rs13266634 mechanism), converging on impaired first-phase insulin release.

The separate 3′-UTR variants rs3802177 and rs11558471 together represent expression- level regulation at the same locus; their joint contribution to allele-specific expression suggests this genomic region is under complex regulatory control that single-variant analyses can miss.

The EVI5 gene¹¹ EVI5 gene
Ecotropic Viral Integration Site 5; originally identified as a retroviral integration site that could activate cellular oncogenes, now recognised as a multifunctional regulator of cell division and vesicle trafficking encodes a protein that belongs to the TBC (Tre-2/Bub2/Cdc16) domain family of GTPase-activating proteins. Its primary cellular job is to activate Rab11, a small GTPase that coordinates the recycling of membrane vesicles during cell division and intracellular transport. EVI5 also stabilises proteins that control cell-cycle re-entry, functioning as an oncogenic driver in some cancers. rs11808092 introduces a missense change in EVI5's coiled-coil domain — one amino acid swapped — that rewires more than half the protein's binding partner network²² rewires more than half the protein's binding partner network
Q612H variant associates with 16 exclusive protein partners absent from wild-type EVI5 and loses associations with several normal partners, reshaping 55% of the interactome. The downstream consequence is an altered interaction with sphingosine 1-phosphate lyase (SGPL1), a key enzyme governing where immune cells can migrate — directly implicating this single amino acid change in multiple sclerosis risk.

The Mechanism

EVI5 contains two principal functional regions: an N-terminal TBC domain³³ TBC domain
TBC = Tre-2/Bub2/Cdc16 homology domain; a conserved catalytic module found in GTPase-activating proteins that switch small GTPases from their active GTP-bound state to their inactive GDP-bound state that acts on Rab11, and a C-terminal coiled-coil domain⁴⁴ coiled-coil domain
A coiled-coil is a structural motif where two or more alpha helices wind around each other; it is a common protein–protein interaction interface that mediates protein–protein interactions. The Q612H substitution sits within this coiled-coil region and exchanges a polar, uncharged glutamine for a positively charged histidine. Structural modelling shows that this charge swap alters the surface hydrophobicity of the domain⁵⁵ alters the surface hydrophobicity of the domain
Computational models predict changes in the electrostatic surface of the coiled-coil that reorient which partners can dock, creating a new docking interface for SGPL1⁶⁶ SGPL1
Sphingosine 1-phosphate lyase — the enzyme that irreversibly degrades sphingosine 1-phosphate (S1P). Its activity is the dominant force creating the S1P concentration gradient between lymphoid organs and blood.

Sphingosine 1-phosphate⁷⁷ Sphingosine 1-phosphate
An intercellular lipid mediator whose steep gradient — high in blood, low in lymphoid organs — functions as a compass that guides lymphocytes from lymph nodes into circulation (S1P) is the signal that licenses T cells to leave lymph nodes and patrol the body. SGPL1 maintains this gradient by degrading S1P in tissues. By acquiring SGPL1 as a novel binding partner, the Q612H variant likely sequesters or modulates SGPL1 activity⁸⁸ sequesters or modulates SGPL1 activity
The interaction with SGPL1 could alter local S1P degradation, disrupting the gradient that controls lymphocyte egress from secondary lymphoid organs, dysregulating the trafficking of autoreactive T cells into the central nervous system — the central pathogenic event in multiple sclerosis. Notably, the drug class fingolimod (Gilenya)⁹⁹ fingolimod (Gilenya)
A first-in-class S1P receptor modulator approved for relapsing MS that traps lymphocytes in lymph nodes, reducing CNS infiltration works by mimicking this very same pathway, underscoring the biological plausibility of the EVI5–SGPL1 connection.

The Evidence

EVI5 emerged as an MS susceptibility locus from the landmark 2007 IMSGC genome-wide association study¹⁰¹⁰ landmark 2007 IMSGC genome-wide association study
The International Multiple Sclerosis Genetics Consortium enrolled >12,000 individuals of European ancestry and identified multiple non-HLA loci; EVI5 was among the first confirmed that scanned the entire genome in thousands of MS patients. The specific rs11808092 Q612H missense variant was then characterised as a non-synonymous coding change almost entirely in linkage disequilibrium¹¹¹¹ linkage disequilibrium
LD measures how often two variants are inherited together; near-complete LD (r²≈1) means they are nearly interchangeable as markers with the intronic tag SNP rs11809700, the strongest signal at the locus.

Hoppenbrouwers et al. (2008)¹²¹² Hoppenbrouwers et al. (2008)
Confirmed EVI5 as a novel MS risk gene in a Dutch isolated population, with replication in 1,318 Canadian MS patients (OR 1.15) demonstrated that EVI5 is genuinely causal rather than a bystander at the locus, with odds ratios of 1.9–2.01 in a genetically isolated population where confounders are minimised.

The largest synthesis came from a 2016 meta-analysis¹³¹³ 2016 meta-analysis
Pooled 16 independent case-control studies from 12 publications comprising 4,600 MS cases and 6,612 controls, predominantly Caucasian populations that assembled 16 independent case-control studies (4,600 MS cases, 6,612 controls) and confirmed rs11808092 is significant across every genetic model tested: per-allele OR 1.17 (95% CI 1.10–1.24), heterozygous OR 1.16, and homozygous OR 1.37. The dose-dependent pattern across CC → AC → AA genotypes is consistent with an additive risk architecture.

At the molecular level, Cabeza-Fernandez et al. (2015)¹⁴¹⁴ Cabeza-Fernandez et al. (2015)
Human Molecular Genetics study used pull-down proteomics and structural modelling to characterise the Q612H interactome change; PMID 26433934 showed that Q612H rewires 55% of the EVI5 protein interaction network, with gene ontology analysis revealing strong enrichment in lipid metabolism — precisely the pathway involved in S1P gradient generation. This study bridges the genetic signal and mechanism in a way rarely achieved for GWAS loci.

Practical Implications

EVI5 rs11808092 contributes modestly but measurably to multiple sclerosis risk. MS is a complex disease with strong HLA contributions (HLA-DR15 is the dominant risk factor), and rs11808092 represents one of many non-HLA loci that cumulatively shape individual risk. Carrying one or two A alleles does not predict MS with high certainty — approximately 95% of A-allele carriers never develop MS — but it shifts the baseline. The risk elevation is analogous to intermediate-effect cardiovascular loci: meaningful in aggregate risk calculations, not deterministic in isolation.

What is actionable: MS is one of the few neurological diseases where early treatment substantially changes long-term outcomes. Disease-modifying therapies are most effective when started at or before the first clinical event. Individuals with this genotype and a family history of MS or unexplained neurological symptoms (vision changes, limb numbness, imbalance, extreme fatigue) should discuss the genetic context with their neurologist. Given the S1P mechanism, the theoretical plausibility of vitamin D and omega-3 supplementation (both modulate immune cell trafficking and neuroinflammation) is especially relevant for A allele carriers — though this connection is not yet proven for rs11808092 specifically.

Interactions

The EVI5 locus sits within a larger GWAS region (chromosome 1p22) spanning GFI1, EVI5, RPL5, and FAM69A. Tag-SNP analysis¹⁵¹⁵ Tag-SNP analysis
Tested 21 putative MS susceptibility variants in the region to map the causal signal has shown that rs11809700 (intronic) and rs11808092 (Q612H) are in near-complete LD and together capture the full regional MS association — the other nearby SNPs do not add independent information.

EVI5 rs11808092 acts through S1P-mediated T-cell trafficking, a pathway mechanistically separate from but clinically parallel to HLA-DRB1*15:01 (tagged by rs3135388), which acts through antigen presentation. Individuals carrying both the high-risk HLA haplotype and the EVI5 A allele accumulate risk from two independent immunological pathways — antigen recognition and lymphocyte mobilisation — potentially magnifying susceptibility beyond what either confers alone, though formal epistasis between these loci has not been reported.

Deep inside your liver cells, a protein called SREBP-1c acts as the master switch for de novo lipogenesis¹¹ de novo lipogenesis
De novo lipogenesis: the biochemical process by which the liver converts carbohydrates into fatty acids and triglycerides for storage. Under normal conditions, insulin turns this switch on after meals — signaling the liver to convert surplus glucose into fat. The rs11868035 variant in the SREBF1 gene alters the regulation of this switch, tipping carriers toward higher triglyceride synthesis, impaired insulin signaling, and a modestly elevated risk of type 2 diabetes.

The Mechanism

SREBF1 (Sterol Regulatory Element Binding Transcription Factor 1) encodes two isoforms from the same locus through alternative promoter usage: SREBP-1a (a broadly expressed, potent transactivator) and SREBP-1c (the liver- and fat-tissue-dominant form that is the primary target of insulin signaling). rs11868035 sits in the 3' UTR and intronic regions of SREBF1, where variants can influence mRNA stability, splicing efficiency, and ultimately protein expression levels of SREBP-1c.

SREBP-1c is synthesized as an inactive precursor anchored to the endoplasmic reticulum. When insulin rises after a meal, the PI3K/Akt pathway triggers its proteolytic cleavage, allowing the mature SREBP-1c fragment to enter the nucleus and activate transcription of lipogenic genes — including fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD1). The rs11868035 risk variant is associated with altered SREBP-1c activity, promoting greater hepatic fat synthesis and contributing to the insulin-resistance cycle: excess hepatic lipid accumulation impairs insulin receptor signaling, further dysregulating glucose and lipid homeostasis.

The Evidence

The most robust human evidence comes from a 15,734-subject Danish cohort study²² 15,734-subject Danish cohort study
Grarup N et al. Diabetes 2008 that linked the minor alleles of rs11868035 and two co-inherited variants (rs2297508, rs1889018; R²=0.6–0.8) to a modestly elevated T2DM risk. For the best-characterized linked variant rs2297508, the per-allele OR for diabetes was 1.17 (95% CI 1.05–1.30, p=0.003); meta-analysis across an additional cohort produced OR 1.08 per allele (p=0.001). Crucially, the risk alleles also associated with elevated plasma glucose at 30 and 120 minutes³³ elevated plasma glucose at 30 and 120 minutes
and elevated serum insulin at 120 min during oral glucose tolerance testing (p<0.006), pointing to impaired glucose clearance rather than fasting hyperglycemia alone.

A Chinese cohort study⁴⁴ Chinese cohort study
Liu JX et al. Diabetes Res Clin Pract 2008 of 327 subjects found significant differences in rs11868035 genotype and allele distributions between T2DM patients and controls (p=0.013 and p=0.001 respectively), and the risk allele was associated with higher LDL cholesterol — consistent with SREBP-1c's role in both triglyceride and cholesterol synthesis. This finding was replicated across a larger 1,141-subject Han and Dongxiang Chinese cohort⁵⁵ 1,141-subject Han and Dongxiang Chinese cohort
Liu JX et al. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012 where the risk allele was identified as a T2DM risk factor in both ethnic groups.

For liver health, a liver stiffness study⁶⁶ liver stiffness study
Müller M et al. Int J Mol Sci 2013 found that risk-allele carriers had significantly higher liver stiffness scores (p=0.029), and the combined effect of carrying both the SREBP1c and PNPLA3 risk genotypes produced substantially greater liver stiffness (p=0.005), suggesting a synergistic lipogenic pathway.

A triglyceride link emerged from a Chinese NAFLD study⁷⁷ Chinese NAFLD study
Peng XE et al. Sci Rep 2016 where the G allele (protective genotype on plus strand) was associated with lower triglyceride levels in healthy controls (p<0.01), and from a Mexican ACS cohort⁸⁸ Mexican ACS cohort
Vargas-Alarcón G et al. PLoS One 2019 showing significant association between rs11868035 and plasma triglyceride levels.

A pharmacogenomics study in 157 schizophrenia patients⁹⁹ 157 schizophrenia patients
Vassas TJ et al. Pharmacogenomics 2014 found that risk-allele carriers had significantly elevated total cholesterol (p=0.01), LDL (p=0.03), and triglycerides (p=0.04) despite statin therapy, suggesting the variant may attenuate statin efficacy — an important clinical consideration.

Practical Actions

The SREBP-1c pathway is acutely responsive to dietary carbohydrate load. Because SREBP-1c is the primary executor of insulin-stimulated lipogenesis, carriers of the risk allele benefit most from strategies that reduce postprandial insulin spikes: limiting refined carbohydrates and added sugars directly curtails the insulin signal that activates SREBP-1c. Monitoring fasting triglycerides and non-HDL cholesterol provides a lipid-specific window into SREBP-1c activity. HbA1c monitoring tracks the slower trajectory toward glucose dysregulation.

The statin-interaction finding warrants attention: if lipid control is inadequate on standard statin doses, the rs11868035 variant may be contributing — a conversation worth having with the prescribing physician.

Interactions

rs11868035 sits in the same lipogenic pathway as PNPLA3 (rs738409), a hepatic lipase variant strongly linked to NAFLD and liver fibrosis. The Müller 2013 study demonstrated that carriers of both variants showed substantially greater liver stiffness than carriers of either alone, suggesting a compound lipogenic burden. This interaction is a strong candidate for a compound action.

Within the SREBP-1c regulatory network, insulin receptor signaling variants (ENPP1 rs1044498, IRS-1 rs2943641) upstream of SREBP-1c activation can compound the downstream lipogenic dysregulation associated with rs11868035.

Your skin is not just a passive envelope — it is an active immune barrier, and filaggrin is one of its most critical structural proteins. FLG (filaggrin) is produced in huge quantities in the outermost layers of the epidermis, where it aggregates keratin filaments¹¹ aggregates keratin filaments
Filaggrin cross-links the keratin cytoskeleton into the dense protein mesh that gives the cornified envelope its mechanical strength and is then enzymatically broken down into natural moisturizing factor (NMF) — the collection of amino acids and derivatives that keeps the stratum corneum hydrated and acidic. The rs12123821 variant lies in the regulatory region of the FLG locus on chromosome 1q21, and the T allele tags a haplotype associated with reduced filaggrin expression. When filaggrin is in short supply, the skin barrier leaks.

The Mechanism

A well-functioning filaggrin layer does two things simultaneously: it locks water in and keeps allergens and microorganisms out. FLG variants that reduce filaggrin expression disrupt both functions in parallel. Transepidermal water loss (TEWL²² TEWL
A standardized measurement of water vapor flux through the skin surface; elevated TEWL means the barrier is leaking water and is correspondingly more permeable to external insults) rises measurably in FLG variant carriers even before any visible eczema appears. At the same time, the disrupted tight junction zone allows environmental allergens — house dust mite proteins, pollen fragments, pet dander, food proteins — to breach the stratum corneum and encounter cutaneous dendritic cells in a pro-inflammatory context rather than the tolerogenic context of the gut. This epicutaneous sensitization route³³ epicutaneous sensitization route
Allergen encountered through the skin primes a TH2 immune response, whereas the same allergen ingested orally typically promotes tolerance is now understood as the primary mechanism initiating the atopic cascade.

The rs12123821 T allele is a common, low-frequency variant (about 4.8% in Europeans, essentially absent in East Asians) that tags this reduced-expression haplotype. Unlike the rare high-penetrance FLG loss-of-function coding mutations (R501X, 2282del4) that completely abolish filaggrin production, rs12123821 represents a more moderate graded impairment — contributing to population-level eczema risk with a well-powered OR of 1.40 in the largest available study.

The Evidence

The primary evidence comes from the largest atopic dermatitis GWAS meta-analysis published to date. Budu-Aggrey et al. (Nature Communications, 2023)⁴⁴ Budu-Aggrey et al. (Nature Communications, 2023)
European and multi-ancestry GWAS meta-analysis of atopic dermatitis highlights importance of systemic immune regulation; Ashley Budu-Aggrey et al., Nat Commun 14:6172, 2023 assembled a discovery cohort of 1,086,394 individuals across 29 studies and a replication cohort of over 3.6 million through 23andMe. At the FLG locus, rs12123821 reached OR=1.40 (95% CI 1.35–1.45, P=4.05×10⁻⁹⁰) in European discovery and OR=1.27 (P=1.4×10⁻²²⁸) in the 23andMe replication — some of the most statistically robust findings in complex disease genetics. A total of 91 AD loci were identified; the FLG region remained the single largest common-variant effect.

The mechanistic link was established in the landmark Palmer et al. (Nature Genetics, 2006)⁵⁵ Palmer et al. (Nature Genetics, 2006)
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis; CA Palmer, IJ McLean et al., Nat Genet 38(4):441–446 study, which showed filaggrin variants "establish a key role for impaired skin barrier function in the development of atopic disease" and that approximately 9% of Europeans carry a FLG loss-of-function allele. Subsequent infant cohort studies quantified the early timeline: Flohr et al. (2011)⁶⁶ Flohr et al. (2011) showed FLG variant carriers already had substantially elevated TEWL (21.59 vs 11.24 g m⁻² h⁻¹) and 4.26-fold eczema odds at just 3 months of age, and the PreventADALL cohort (2022)⁷⁷ PreventADALL cohort (2022) (1,836 infants) confirmed OR=2.89 for early eczema onset. The downstream consequence reaches beyond eczema: the Venkataraman et al. (2014)⁸⁸ Venkataraman et al. (2014) Isle of Wight cohort demonstrated that FLG loss-of-function mutations carry striking food allergy risk (OR=31.46 at age 10), mediated entirely through the prior eczema state and epicutaneous sensitization.

Practical Actions

The core strategy for FLG variant carriers has two components: reinforcing the deficient barrier from outside, and reducing exposure to triggers that exploit the barrier gap. High-lipid emollients — particularly those formulated with ceramides, the lipid class that fills the intercellular spaces of the stratum corneum — can partially compensate for reduced filaggrin-derived NMF. Frequency and coverage matter: casual daily moisturizing is not equivalent to therapeutic barrier maintenance. Environmental allergen mitigation (house dust mite covers, avoidance of certain preservatives such as methylisothiazolinone in skincare products) is particularly valuable for FLG variant carriers because their barrier lets these sensitizers through more readily. Proactively managing known eczema flare triggers — rather than reacting after the fact — is the evidence-based posture for this genotype.

Interactions

FLG variant status interacts with environmental allergen burden: the same FLG haplotype that increases eczema risk in a high-allergen household may have attenuated effects in a lower-allergen environment, suggesting that allergen exposure amplifies the genetic risk. Within the atopic cascade, rs12123821 T-allele carriers who develop eczema early face substantially higher risk for subsequent asthma and food allergy compared to individuals whose eczema has non-FLG genetic drivers — because FLG-driven eczema specifically creates the epicutaneous sensitization route. Related FLG locus variants rs61816761 and rs558269137 encode the classical high-penetrance loss-of-function coding mutations (R501X and 2282del4) with larger individual effect sizes but much lower population frequencies; rs12123821 captures additional population-level risk at the same locus via regulatory architecture.

Cholesteryl ester transfer protein (CETP) is the molecular shuttle that remodels your lipoprotein particles. Operating in blood plasma, it exchanges cholesteryl esters¹¹ cholesteryl esters
lipid molecules in which cholesterol is esterified with a fatty acid — the main cargo form of cholesterol inside lipoprotein particles from HDL particles for triglycerides from VLDL and LDL. The net effect: each CETP transaction depletes HDL of cholesterol and returns that cholesterol to the atherogenic lipoprotein pool. More CETP activity means lower HDL-C; less activity means higher HDL-C.

rs12447924 is a C/T variant located approximately 1,700 bases upstream of the CETP transcription start site, within the gene's promoter region. It sits in a tightly linked haplotype block along with rs3764261 (−2568), the GWAS lead SNP for this region, and rs4783961 (−998), three tagSNPs in strong linkage disequilibrium (D′=0.92–0.97) that collectively mark one of the most replicated HDL-cholesterol loci in the human genome. The T allele at rs12447924 is part of the HDL-raising 'ATAA' promoter haplotype; the C allele marks the HDL-lowering 'CTAG' haplotype.

The Mechanism

Upstream variants in this haplotype block regulate CETP transcription in the liver. The HDL-raising haplotype — tagged by the T allele at rs12447924 — is associated with reduced CETP gene expression and lower plasma CETP activity. With less CETP protein secreted, the rate of cholesteryl ester transfer from HDL to VLDL slows, allowing HDL particles to retain more of their cholesterol cargo and circulate at higher concentrations.

The promoter haplotype containing the C allele at rs12447924 is associated with normal-to-higher CETP expression, maintaining the full cholesterol transfer rate and producing lower circulating HDL-C. Mechanistic studies examining adjacent upstream variants (rs247616, in near-complete LD with this block) confirm that these upstream elements act as transcriptional enhancers in hepatocytes: the minor-frequency variants reduce luciferase reporter activity by approximately 1.7-fold in HepG2 cells²² 1.7-fold in HepG2 cells
Chasidah Oommen et al., Regulation of CETP expression by upstream polymorphisms, Atherosclerosis 2015. This directly links the promoter haplotype to the amount of CETP protein produced, not just its enzymatic activity per molecule.

The Evidence

The most detailed genotype-level data for rs12447924 comes from the Sikh Diabetes Study³³ Sikh Diabetes Study
Wander et al., n=2,431 individuals stratified by glycemic status, where haplotype analysis showed the ATAA haplotype (T allele at rs12447924) associated with +2.71 mg/dL higher HDL-C (p=6.38×10⁻⁵) in normoglycemic individuals, and the CTAG haplotype (C allele at rs12447924) associated with −1.78 mg/dL lower HDL-C (p=0.025).

Because rs12447924 is in strong LD with the GWAS lead SNPs for this region, studies of those neighboring variants provide the broadest evidence base. The Women's Health Study⁴⁴ Women's Health Study
Ridker et al., n=18,245, average 10-year follow-up found that CETP haplotype variants in this block were associated with 3.1 mg/dL higher HDL-C and a 24% lower risk of myocardial infarction (HR 0.76, 95% CI 0.62–0.94). A genome-wide meta-analysis of statin response⁵⁵ genome-wide meta-analysis of statin response
Postmus et al., n=27,720 found the CETP locus to be the only genome-wide significant predictor of HDL-C increase during statin treatment, with the HDL-raising haplotype predicting a greater HDL response to statins.

The gene-diet interaction evidence is clinically meaningful. In the combined POUNDS LOST and DIRECT randomized trials⁶⁶ POUNDS LOST and DIRECT randomized trials
Ma et al., n=894 total, individuals carrying the CETP upstream haplotype in the HDL-lowering direction showed significantly smaller HDL-C improvements on low-fat diets compared to high-fat diets (11.7 vs 4.5% increase, p<0.001). The SNAP trial⁷⁷ SNAP trial
Economos et al., n=524 young adults further showed that the HDL-lowering CETP genotype predicted declining HDL-C over time in the untreated control arm, but this trajectory was eliminated in the lifestyle intervention arm — demonstrating that the genetic disadvantage is modifiable.

Practical Actions

For TT homozygotes (~58% of Europeans): your CETP promoter is biased toward the HDL-raising haplotype. HDL-C levels are expected to be in the upper range for your demographic. Standard lipid monitoring applies.

For CT heterozygotes (~36% of Europeans): one C allele places you in an intermediate position. HDL-C may trend slightly lower than TT individuals. Limiting saturated fat intake and maintaining a healthy omega-3 to omega-6 ratio preserves your HDL level.

For CC homozygotes (~6% of Europeans): two C alleles orient your CETP promoter toward full expression and maximum cholesteryl ester transfer rate. HDL-C is expected to be below-average. The gene-diet evidence specifically supports choosing higher dietary fat quality (replacing saturated fat with polyunsaturated fats) over a low-fat approach when managing HDL. Checking both HDL-C and ApoA-I gives a more complete cardiovascular picture than HDL-C alone.

Interactions

rs12447924 is in strong linkage disequilibrium (D′=0.92–0.97) with rs3764261, the GWAS lead SNP for the CETP upstream haplotype block, and with rs247616, the variant most directly implicated in transcriptional regulation. Genetic tests may report any of these three; they largely tag the same underlying haplotype effect. rs708272 (TaqIB, intron 1) is in the same gene but a different LD block — it adds independent HDL-C variance on top of the upstream haplotype.

The LIPC rs1532085 variant also modulates HDL-C levels through hepatic lipase activity rather than CETP-mediated transfer. When both a CETP upstream C-allele genotype and a LIPC A-allele genotype co-occur, the two mechanisms partially counteract each other: reduced CETP activity (LIPC A allele, fewer transfers) tends to raise HDL, while the CETP C-allele haplotype tends to lower it. The net HDL-C level depends on which effect predominates, and particle-level testing (NMR lipoprofile) is more informative than total HDL-C in individuals carrying both variants.

CYP3A4 is the most abundant drug-metabolizing enzyme in the human liver, responsible for the biotransformation of approximately 50% of all clinically used medications¹¹ 50% of all clinically used medications
Including statins, immunosuppressants, calcium channel blockers, benzodiazepines, chemotherapy agents, and many antibiotics. The CYP3A4*16B haplotype, defined primarily by the rs12721629 variant, carries a missense substitution (Thr185Ser in older literature numbering; p.Leu373Val in current HGVS notation using transcript NM_017460.6) that alters the enzyme's active site geometry in a way that affects different drug substrates to different degrees.

This variant is largely confined to Japanese and broader East Asian populations, where heterozygous carriers appear in roughly 3-4% of individuals. In European, African, and South Asian populations it is essentially absent. The CYP3A4 gene itself sits on the minus strand of chromosome 7, so the coding-strand change (c.554C>G in older transcript notation, c.1117C>G in NM_017460.6) is reported on the plus strand as G>C at chromosomal position 99,762,177 (GRCh38).

The Mechanism

The Thr185Ser substitution (threonine-to-serine at position 185 in the older protein numbering) changes a hydroxyl-bearing residue in the substrate-binding channel of CYP3A4. In vitro studies using recombinant enzyme²² In vitro studies using recombinant enzyme
CYP3A4*16 expressed in Sf21 insect cells co-expressing human NADPH-P450 reductase revealed that the effect is strikingly substrate-dependent: intrinsic clearance of midazolam (a standard CYP3A4 probe) fell by about 50% for the primary 1'-hydroxylation pathway and 30% for 4-hydroxylation, while carbamazepine epoxidation dropped by 74%. This contrast with, for example, CYP3A4*22, which reduces enzyme expression uniformly across substrates, suggests the *16B substitution changes the substrate access channel geometry rather than overall protein stability or expression.

The kinetic mechanism differs by substrate. For midazolam, the variant shows elevated Km (reduced binding affinity) with lower Vmax. For carbamazepine, the changes are more complex and consistent with a distorted two-site cooperative binding model, suggesting the variant may disrupt allosteric activation normally seen with this substrate.

The Evidence

The most clinically informative data comes from two studies in Japanese cancer patients. Sai et al. examined 235 patients³³ Sai et al. examined 235 patients
paclitaxel pharmacokinetics measured in 229 with usable plasma samples receiving paclitaxel chemotherapy and identified eight *16B carriers (all heterozygotes). Carriers showed a 20% lower median AUC ratio for the 3'-p-hydroxylation metabolite and a 2.4-fold higher ratio for the 6α-hydroxylation product (P<0.001), indicating that CYP3A4*16B shifts paclitaxel metabolism away from the 3'-p-hydroxylation route toward the 6α-hydroxylation route — with potential consequences for drug efficacy and metabolite toxicity profiles.

Sai et al. studied 177 Japanese cancer patients⁴⁴ Sai et al. studied 177 Japanese cancer patients
Irinotecan pharmacokinetics with CYP3A4 haplotype analysis receiving irinotecan and found that male patients carrying *16B had approximately 50% lower APC/irinotecan ratios, indicating significantly reduced CYP3A4-mediated oxidative metabolism of this anticancer drug. No female *16B carriers were enrolled. Although overall irinotecan total clearance was not significantly different between genotypes — suggesting compensatory pathways — the altered metabolite ratios could affect the balance between efficacy and toxicity (the APC pathway is thought to be a detoxification route).

Maekawa et al.⁵⁵ Maekawa et al.
Kinetic characterization of CYP3A4.16 in insect cell microsomes provided the mechanistic foundation: recombinant CYP3A4*16 shows 50% reduced intrinsic clearance for midazolam 1'-hydroxylation, 30% for midazolam 4-hydroxylation, and 74% for carbamazepine 10,11-epoxide formation, confirming that the magnitude of impairment varies considerably by substrate.

CYP3A4*16B is not included in current CPIC or DPWG clinical guidelines, which focus on CYP3A4*22 (rs35599367) and the CYP3A5 *1/*3 system (rs776746) as the established pharmacogenomic variants for CYP3A4 pathway guidance. The rarity of *16B outside East Asian populations limits the evidence base for formal guideline development.

Practical Actions

Because CYP3A4*16B is heterozygous in virtually all carriers and causes moderate, substrate-dependent activity reduction, the clinical impact depends heavily on which drugs you take. For chemotherapy drugs like paclitaxel and irinotecan, the altered metabolite ratios could affect both efficacy and the toxicity profile — oncologists should be aware that standard dosing may produce different metabolite distributions in *16B carriers. For drugs with narrow therapeutic windows (carbamazepine, tacrolimus), the 50-74% reduction in intrinsic clearance observed in vitro suggests that doses appropriate for normal CYP3A4 metabolizers may need adjustment.

The absence of CYP3A4*16B from clinical pharmacogenomic panels used in Western countries means carriers are unlikely to receive a pharmacogenomic alert for this specific variant. East Asian patients undergoing comprehensive pharmacogenomic testing may benefit from inclusion of this variant.

Interactions

CYP3A4*16B's effects are additive with other reduced-function CYP3A variants. Individuals of East Asian ancestry who carry both CYP3A4*16B and CYP3A5*3/*3 (rs776746 CC, the most common genotype globally) would have reduced function in both CYP3A enzymes, potentially reaching total CYP3A activity levels comparable to carriers of CYP3A4*22 in European populations.

The substrate-dependent nature of *16B also means that drug-drug interactions can produce unpredictable results. A CYP3A4 inhibitor like itraconazole that uniformly blocks enzyme activity may have a larger relative impact on carbamazepine (already 74% reduced) than on midazolam (50% reduced) in *16B carriers, since both baseline activities start from a lower point. Conversely, inducers like rifampin may partially rescue activity in *16B by upregulating enzyme expression to compensate for per-molecule inefficiency.

The CYP3A4*22 variant (rs35599367) is a separate, more common, and better-studied reduced-function allele that should be tested alongside *16B in East Asian patients receiving narrow therapeutic index CYP3A4 substrates.

The PER3 gene¹¹ PER3 gene
Period Circadian Regulator 3, one of the three Period proteins forming the negative feedback arm of the molecular circadian clock encodes a protein that accumulates during the day, translocates into the nucleus, and represses the CLOCK-BMAL1 transcription complex that drove its own synthesis — completing one full oscillation every ~24 hours. The rs139315125 variant introduces an arginine at position 417 where histidine normally sits, and it almost always arrives in combination with the rs150812083 Pro415Ala change, seven base pairs upstream on the same chromosome copy.

On its own, H417R is classified as conflicting significance in ClinVar — most recent submissions rate it as uncertain or likely benign, reflecting the difficulty of deconvolving individual contributions when the two changes always co-occur. Its primary clinical importance is as the second component of the compound P415A/H417R haplotype that causes familial advanced sleep phase syndrome 3 (FASPS3)²² familial advanced sleep phase syndrome 3 (FASPS3)
An autosomal dominant circadian rhythm disorder characterized by sleep onset 4-6 hours earlier than population average, with spontaneous waking around 4 AM, and associated seasonal mood vulnerability.

The Mechanism

PER3 protein stability depends critically on the local structure of its PAS domain³³ PAS domain
PER-ARNT-SIM domain — a conserved protein-protein interaction module shared across clock proteins, used by PER proteins to dimerize and interact with CRY repressor partners. At position 417, histidine contributes to the hydrogen-bonding network that stabilizes this domain. The G allele substitutes the positively charged, bulkier arginine, perturbing the local fold and — when combined with the adjacent Pro415Ala substitution — produces a protein that degrades faster and accumulates to lower nuclear concentrations despite elevated mRNA production.

Zhang et al. (PNAS, 2016)⁴⁴ Zhang et al. (PNAS, 2016)
Zhang L et al. A PERIOD3 variant causes a circadian phenotype and is associated with a seasonal mood trait. PNAS 113(11):E1536-44. showed that PER3-P415A/H417R has reduced transcriptional repressor activity across multiple titers compared with wild-type PER3, and loses the ability to stabilize both PER1 and PER2 — compounding the clock acceleration. Transgenic mice expressing the compound human allele showed altered circadian period under constant light conditions and depression-like behavior under short photoperiod, directly linking the destabilized PER3 to seasonal affective phenotypes.

The Evidence

The P415A/H417R compound haplotype was characterized in a three-generation family with FASPS3 by Zhang et al. (PNAS 2016, PMID 26903630). Affected members fell asleep by midnight and woke spontaneously by 8:15 AM (~4 hours earlier than average), and scored at the 97th–99th percentile for seasonal mood variation with worst symptoms in December and January. All published functional studies tested the two substitutions together; the individual contribution of H417R alone was not deconvolved, which explains the conflicting ClinVar classifications.

At the population level, the G allele of rs139315125 is rare: ~0.58% in Europeans, ~0.04% in Africans, and ~0.005% in East Asians (gnomAD exomes). Given the near- perfect co-occurrence with rs150812083 G on the same chromosome, allele frequencies and phenotypic associations are effectively shared between the two entries. The Jones et al. 2019 GWAS (Nature Communications, 697,828 individuals) identified the PER3 locus as contributing to extreme morningness chronotype with an odds ratio of 1.44, and objective sleep timing ~8 minutes earlier by actigraphy.

ClinVar accession VCV000242411 currently reflects conflicting classifications (1 pathogenic, 2 uncertain significance, 1 likely benign), with the pathogenic call resting on co-segregation in the FASPS3 family; the uncertain and likely benign calls reflect the difficulty of attributing causality to one variant when it always co-occurs with a second.

Practical Implications

Carriers of this variant who do not also carry the rs150812083 G allele face genuinely uncertain phenotypic impact — the functional evidence is for the compound haplotype. Carriers who are positive at both positions have a biologically accelerated clock: an intrinsic circadian period shorter than 24 hours that advances the entire sleep-wake cycle. The degree of phase advance varies with environment and other genetic modifiers, but the affected FASPS3 family consistently showed 4-hour advances.

Evening bright light therapy — exposure between 7 and 9 PM — is the most evidence-supported intervention for advanced sleep phase. Light in this window falls in the phase-delay zone of the circadian phase response curve⁵⁵ circadian phase response curve
The PRC describes how light exposure at different clock times shifts the circadian oscillator; late-evening light delays the clock, early-morning light advances it, counteracting the pathological advance. Avoiding bright light in the first hour after waking prevents compounding the phase shift further.

Interactions

rs139315125 (H417R) and rs150812083 (Pro415Ala) sit seven base pairs apart and are almost always inherited together on the same chromosome as the FASPS3 compound haplotype. Functionally, both changes contribute to PER3 protein destabilization; the compound state produces more severe clock acceleration than either change alone based on current evidence.

The same circadian feedback loop involves rs228697 (PER3 Pro864Ala), which lengthens circadian period (evening-shifting) rather than shortening it. An individual carrying both an evening-shifting PER3 variant and this morning- advancing haplotype would experience opposing molecular forces, potentially producing an unstable or irregular circadian rhythm. rs35333999 (PER2 V903I) is another evening-shifting component in the same repressor complex.

The seasonal mood dimension creates a plausible interaction with melatonin pathway variants, particularly rs10830963 (MTNR1B), though no published study has formally characterized compound H417R/MTNR1B carriers.

Every cell in the small intestine and kidney proximal tubule faces a fundamental challenge: cationic amino acids — lysine, arginine, and ornithine¹¹ lysine, arginine, and ornithine
These positively charged (cationic) amino acids are essential for protein synthesis, urea cycle function, and nitric oxide production. They share a common transporter because of their similar charge and size properties — must be absorbed across the basolateral membrane and returned to the bloodstream. SLC7A7 encodes y+LAT1, the catalytic subunit of the heterodimeric transporter that performs this export step. When both copies of SLC7A7 are disrupted, cationic amino acids become trapped inside intestinal and renal tubular cells, never reaching the bloodstream in meaningful quantities after meals. The result is lysinuric protein intolerance (LPI)²² lysinuric protein intolerance (LPI)
OMIM #222700 — autosomal recessive aminoaciduria; Finnish prevalence 1:60,000; worldwide approximately 200 documented cases.

The c.895-2A>T change (NM_003982.4) obliterates the acceptor splice site at the 5′ end of exon 7 of SLC7A7. Because SLC7A7 is transcribed from the minus strand of chromosome 14, the plus-strand (genome file) change is T>A at position 22,775,938. In Finnish patients, this single mutation accounts for essentially all LPI cases — a founder effect from a single ancestral carrier whose descendants spread through the Finnish population over centuries. In the rest of the world, LPI arises from compound heterozygosity among the ~60 known pathogenic SLC7A7 variants; c.895-2A>T is rare outside Finland.

The Mechanism

The c.895-2A>T transversion converts the invariant AG of the intron 6 splice acceptor consensus to TG. Spliceosomes cannot recognize this disrupted consensus, and normal exon 7 inclusion is abolished. The aberrant splicing creates a 10-bp deletion at the start of exon 7, shifting the reading frame and generating a premature stop codon 26 codons downstream. The truncated y+LAT1 protein retains no residual transport activity and is retained intracellularly rather than trafficking to the plasma membrane — a complete loss of function.

Without functional y+LAT1 at the basolateral membrane, cationic amino acids accumulate in intestinal epithelial cells and are excreted in urine rather than reabsorbed. Plasma lysine, arginine, and ornithine fall chronically low. Arginine deficit impairs urea cycle function, causing postprandial hyperammonemia³³ postprandial hyperammonemia
Ammonia normally converted to urea via the ornithine-citrulline-arginine cycle cannot proceed efficiently when ornithine and arginine are deficient; citrulline supplementation bypasses this block by providing a urea-cycle intermediate via a neutral amino acid transporter that is not affected by the SLC7A7 defect. Intracellular arginine trapping also drives excessive nitric oxide (NO) synthesis, which Mannucci et al.⁴⁴ Mannucci et al.
Mannucci et al., J Inherit Metab Dis, 2005 — elevated plasma nitrate and enhanced nitrite production from LPI fibroblasts propose as a unifying mechanism for the diverse multi-organ complications of LPI.

The Evidence

LPI was recognised as a distinct genetic disease in Finland in the 1960s, but its molecular basis remained unknown until 1999, when two groups simultaneously identified SLC7A7 mutations as the cause. Torrents et al.⁵⁵ Torrents et al.
Torrents et al., Nature Genetics, 1999 — identified the gene encoding y+LAT1; confirmed transport abolition in Xenopus oocyte functional assay showed that the Finnish founder allele completely abolished transport of cationic amino acids when expressed in Xenopus oocytes with the heavy chain partner 4F2hc.

Sperandeo et al.⁶⁶ Sperandeo et al.
Sperandeo et al., Human Mutation, 2008 — comprehensive mutation analysis, 130 patients, ≥98 families, 43 distinct variants described 43 distinct pathogenic SLC7A7 variants and confirmed that c.895-2A>T is the sole founder allele in Finland. Despite sharing the same homozygous genotype, Finnish LPI patients show extreme phenotypic variability — ranging from mild growth failure to life-threatening pulmonary alveolar proteinosis — with no genotype-phenotype correlation.

Tringham et al.⁷⁷ Tringham et al.
Tringham et al., Mol Genet Metab, 2012 — genome-wide microarray in Finnish LPI patients vs controls; 926 differentially expressed genes used genome-wide microarray analysis to show that the Finnish founder mutation triggers widespread secondary transcriptional dysregulation — 926 differentially expressed genes enriched in inflammatory response, immune system processes, and apoptosis pathways. This explains why LPI is far more complex than a simple amino acid transport defect.

Multi-organ complications are well characterised from long-term Finnish cohort data: pulmonary alveolar proteinosis occurs in a significant subset and can be fatal; renal disease including immune complex-mediated glomerulonephritis and proximal tubular dysfunction develops over decades; hemophagocytic lymphohistiocytosis/macrophage activation syndrome is a recognized life-threatening complication; and autoimmune manifestations including lupus-like disease have been reported. Parto et al.⁸⁸ Parto et al.
Parto et al., Human Pathology, 1994 — autopsy findings in 4 Finnish pediatric LPI fatalities documented pulmonary alveolar proteinosis, immune complex glomerulonephritis, hepatic dysfunction, and amyloid deposits across all four cases.

Practical Actions

For confirmed homozygous individuals, management is lifelong and requires a metabolic specialist. The two pillars are:

1. Dietary protein restriction (0.8–1.5 g/kg/day in children; 0.5–0.8 g/kg/day in adults) to limit the postprandial cationic amino acid load that cannot be handled by deficient y+LAT1.

2. Oral citrulline supplementation (≤100 mg/kg/day in 4 divided doses) — citrulline is a neutral amino acid transported by intact systems, bypassing the y+LAT1 defect. It replenishes the urea cycle's ornithine supply, normalising ammonia clearance after meals and permitting modestly higher protein intake.

L-lysine-HCl (20–30 mg/kg/day) can partially correct lysine deficiency but does not address arginine or ornithine. Carnitine (25–50 mg/kg/day) is added when hypocarnitinemia is documented. Nitrogen-scavenger drugs (sodium benzoate, sodium phenylacetate) are used for acute hyperammonemic crises alongside IV arginine and dextrose.

Carriers (one copy) are clinically and biochemically normal; no dietary restrictions or treatment is needed.

Interactions

Compound heterozygotes carrying c.895-2A>T on one chromosome and a different pathogenic SLC7A7 variant on the other also develop full LPI. Because the Finnish founder allele is rare outside Finland, non-Finnish LPI patients are typically compound heterozygous for two different SLC7A7 variants.

The LPI urea cycle defect interacts with arginine-dependent nitric oxide synthesis. Intracellular arginine trapping elevates NO production, which may mediate pulmonary, renal, and immune manifestations independently of the systemic amino acid deficiency — suggesting that treatment targeting only hyperammonemia may be insufficient to prevent end-organ damage.